SEPN’s SEP-479 phase I data expected in Q1 next year
SEP-479, an oral PTH receptor agonist, is advancing with phase I data expected in Q1 next year. The program targets improved calcium control and patient adherence, with additional updates for Graves’, osteoporosis and mast cell diseases.
SEP-479, an oral PTH receptor agonist, is advancing with phase I data expected in Q1 next year, with the goal of improving calcium control and patient adherence. The pipeline also includes programs for Graves', osteoporosis and mast cell diseases, while platform innovations are being used to support new drug discovery. Updates…